ATARA Biotherapeutics (NASDAQ: ATRA) reported Q1 EPS of ($0.86), $0.06 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $3.55 million versus the consensus estimate of $1.6 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.